Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safusidenib for Newly Diagnosed IDH1-mutant WHO Grade 3 Glioma
NCT07832123Phase 2Not yet recruiting
- Sponsor
- University of Zurich
- Start
- Mar 2027
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of safusidenib in glioma, sponsored by University of Zurich. Primary endpoint: Progression-Free Survival at 12 months. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
safusidenib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07832123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07832123.